The University of Texas System

The Scripps Research Institute

Whitehead Institute

The Universty of Texas System,board of Regents

Sendurai A Mani

Peter G Schultz

Luke L Lairson

Michael J Bollong

Robert Allan Weinberg

Michael Andreeff

Mai-Jing Liao

Venkata Battula

Tapasree Roy Sarkar

The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

Small molecule inhibitors of cancer stem cells and mesenchymal cancer types

The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.

Methods for determining the presence of cancer stem cells by detecting GD2 expression. Also provided are methods for reducing proliferation of cancer stem cells by contacting the cells with a GD2 targeting agent, such as an anti-GD2 antibody or a GD3 synthase inhibitor. GD3 synthase inhibitor compounds are also provided.

Ganglioside GD2 as a marker and target on cancer stem cells

Methods for preparing progenitor cells are described where epithelial cells are induced to undergo epithelial-mesenchymal transition as a result of exposure to an inducing agent or introduction of a gene therein that induces epithelial-mesenchymal transition. Progenitor cells resulting therefrom have use in cell-based therapies, among other utilities.

Progenitor cells and uses thereof

Growing community of inventors

Houston, TX, United States of America

Sendurai A Mani